Cost–benefit analysis of the National Immunization Program in Spain-Reference-Cited by-同舟云学术

Cost–benefit analysis of the National Immunization Program in Spain

Published:2024-08-19 Issue:1 Volume:20 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Pérez Alberto¹,Fernández Prada María²,Cassinello Natalia³,Vallejo-Aparicio Laura Amanda⁴^ORCID,García Andrea⁴^ORCID,González Almudena⁵,Durán Ana⁵,Zozaya Néboa⁵,Fernández Irene⁵,Daheron Mathilde⁵,Hidalgo Álvaro⁶⁷,Beck Ekkehard⁸,García Ruiz Antonio⁹

Affiliation:

1. Management, Hospital Nuestra Señora De Sonsoles (Complejo Asistencial De Avila), Ávila, Spain

2. Preventive Medicine and Public Health, Hospital Vital Alvarez Buylla, Asturias, Spain

3. Financial and Accounting Management, Universidad Pontificia Comillas, Madrid, Spain

4. Market Access, GSK, Madrid, Spain

5. Health Economics and Market Access, Vivactis Weber, Madrid, Spain

6. Weber Foundation, Madrid, Spain

7. University of Castilla La Mancha, Toledo, Spain

8. Value Evidence and Outcomes, GSK, Wavre, Belgium

9. IBIMA Platform Bionand, Universidad de Málaga – IBIMA Platform Bionand, Málaga, Spain

Funder

GlaxoSmithKline

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2385175

Reference57 articles.

1. World Health Organization (WHO). Vaccines and immunization. 2022. [accessed 2023 Apr 5]. https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1.

2. A cost-benefit analysis of varicella vaccination in Aragón

3. Reduction of Direct Health Costs Associated with Pertussis Vaccination with Acellular Vaccines in Children Aged 0–9 Years with Pertussis in Catalonia (Spain)

4. Estimación del impacto de la vacunación antigripal con adyuvante MF59 en población mayor de 64 años para el Sistema Nacional de Salud: efectos y costes

5. Cost–effectiveness analysis of quadrivalent influenza vaccine in Spain